Inhalation Sciences Sweden AB (ISAB)
Market Closed
10 Aug, 15:25
XSTO XSTO Primary kr
0. 18
0
0%
kr
51.42M Market Cap
- P/E Ratio
- Div Yield
102,793 Volume
- Eps
kr 0.18
Previous Close Want to track ISAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ISAB closed today higher at kr0.18, an increase of 0% from yesterday's close, completing a monthly increase of 0% or kr0.18. Over the past 12 months, ISAB stock gained 0%.
ISAB is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Inhalation Sciences Sweden AB (ISAB) FAQ
What is the stock price today?
The current price is kr0.18.
On which exchange is it traded?
Inhalation Sciences Sweden AB is listed on XSTO.
What is its stock symbol?
The ticker symbol is ISAB.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 51.42M.
Has Inhalation Sciences Sweden AB ever had a stock split?
No, there has never been a stock split.
Inhalation Sciences Sweden AB Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Manoush Masarrat CEO | XSTO Exchange | - ISIN |
| SE Country | 8 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Inhalation Sciences Sweden AB (publ), established in 2004 and based in Huddinge, Sweden, specializes in the development and sales of labtech equipment aimed at inhalation research. The company's mission is to provide advanced tools and systems that enable scientists to explore and understand the impact of inhaled particles on lung health effectively.
Products and Services
- PreciseInhale: This innovative laboratory system offers scientists a precise method to measure the behavior of inhaled particles within the lungs and their subsequent effects on health. It supports detailed analysis of particle inhalation and deposition patterns, facilitating targeted research into respiratory drug delivery and toxicology.
- DissolvIt: A cutting-edge in vitro simulation system, DissolvIt allows for the detailed study of how respirable particles dissolve and are absorbed by the lung epithelium. This technology bridges the gap between in vivo studies and traditional in vitro tests, offering more realistic models of human pulmonary absorption.
- XposeALI: This 3D cell exposure module uniquely integrates aerosol exposure capabilities with advanced 3D cell cultures maintained at an air-liquid interface. It enables more physiologically relevant studies of cell responses to inhaled substances, making it a valuable tool for evaluating drug efficacy and safety.
- Nose-only inhalation: Recognized as a standard method in the preclinical testing of inhalation drugs and for conducting inhalation toxicity studies in rodents. This technique focuses on exposing the nose to test substances, thus replicating human exposure more closely than whole-body exposure methodologies.
- Intratracheal exposure module: Offering a unique approach to delivering aerosols directly to the lungs, this technology bypasses the nasal passages to target the lungs directly. It is specially designed for use with spontaneously breathing rodents, providing a more refined model for studying lung-specific effects of inhaled compounds.
Contact Information
Address: Novum floor 6, Huddinge, Sweden, 141 57
Phone: 46 7 05 62 51 95
Website: https://www.inhalation.se
